SCHEMBL5147453

SCHEMBL5147453

Cc1cccc(C(=C2C(=O)NNC2=O)c2ccc(-c3ccc(C(=O)O)cc3)o2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.42
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
GAA P10253 2/20 0.40
PKM P14618 1/20 0.40
RECQL P46063 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
APEX1 P27695 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
SLC9A1 P19634 1/20 0.40
MEN1 O00255 2/20 0.39
INSR P06213 1/20 0.39
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5189038 0.84 CDK2 (0.48) KCNH2KDM4EALDH1A1KMT2APOLB
SCHEMBL5145311 0.79 GSK3A (0.51) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL5188402 0.72 CDK2 (0.48) KDM4EALDH1A1KMT2AMAPTPOLB
SCHEMBL3758734 0.71 CDK2 (0.47) KDM4EALDH1A1HPGDKMT2APOLB
SCHEMBL5145369 0.71 PTPN1 (0.43) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL5735124 0.71 ALDH1A1 (0.50) ALDH1A1HPGDMAPTGAACTDSP1
SCHEMBL244341 0.68 NR4A1 (0.67) KCNH2KDM4EALDH1A1HPGDKMT2A
SCHEMBL12877043 0.68 SLC9A1 (0.51) KCNH2KDM4EALDH1A1KMT2APOLB
SCHEMBL5147288 0.68 GSK3B (0.44) KDM4EALDH1A1HPGDKMT2AMAPT
SCHEMBL700768 0.68 ALDH1A1 (0.56) KDM4EALDH1A1HPGDKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KCNH2 4064/4885KDM4E 4569/4885ALDH1A1 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.